Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00724984 · OUTCOME

Phase II: Overall Response Rate (CR+PR)

Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma · Source last updated 2014-04-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of Participants
Interval / dispersion
95% Confidence Interval
Time frame
From first response assessment (day 22 to 28 of Cycle 2) to last response assessment on day 22-28 in even-numbered cycles

Groups in this outcome

Follicular/Phase II (Efficacy)

Not reported

Mantle Cell Lymphoma/Phase II (Efficacy)

Not reported

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Follicular/Phase II (Efficacy)16
Mantle Cell Lymphoma/Phase II (Efficacy)14

Reported measurements

Source class 1
Values in Percentage of Participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Follicular/Phase II (Efficacy)56.3Not reported29.980.2Not reported
Mantle Cell Lymphoma/Phase II (Efficacy)21.4Not reported4.6650.8Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        29.9
        upper Limit
        80.2
        value
        56.3
      2. group Id
        OG001
        lower Limit
        4.66
        upper Limit
        50.8
        value
        21.4
denoms
  1. counts
    1. group Id
      OG000
      value
      16
    2. group Id
      OG001
      value
      14
    units
    Participants
dispersion Type
95% Confidence Interval
groups
  1. id
    OG000
    title
    Follicular/Phase II (Efficacy)
  2. id
    OG001
    title
    Mantle Cell Lymphoma/Phase II (Efficacy)
param Type
NUMBER
reporting Status
POSTED
time Frame
From first response assessment (day 22 to 28 of Cycle 2) to last response assessment on day 22-28 in even-numbered cycles
title
Phase II: Overall Response Rate (CR+PR)
type
PRIMARY
unit Of Measure
Percentage of Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice